In patients with breast cancer, 23.4% (18/77) of the pathogenic/likely pathogenic variants were found in BRCA1 whereas 48.1% (37/77) were located in BRCA2. Regarding ovarian cancer, pathogenic mutations were found in 38.5% (5/13) and 53.8% (7/13) for BRCA1 and BRCA2 respectively. This evidence concerns the gene BRCA1 and ovarian carcinoma.